Quotables
"Inventing is a combination of brains and materials. The more brains you use, the less material you need."
Charles Kettering
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 5708034 | Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them Sulfonimidamides of the formula I ##STR1## in which at least one of the three substituents R(1), R(2) and R(3) is a ... | 01/13/1998 |
| 5698537 | Method of lowering the viscosity of mucus The use of phospholipids of the following formula to reduce the viscosity of mucus in a patient is described: ##STR1## wherein one of X, Y, or Z represent: ##STR2## in which each R represents hydrogen or methyl, and each of the other two of... | 12/16/1997 |
| 5686114 | Uses of inorganic pyrophosphates Pharmaceutical compositions comprising an inorganic pyrophosphate (PPi) in a form that renders the PPi accessible to ABC proteins when administered to a subject in vivo, as well as use of the compositions for treating subjects having a disease or disorder... | 11/11/1997 |
| 5674483 | Treatment for diseases involving inflammation The present invention relates to a method to protect an animal from a disease involving inflammation by treating that animal with an effective amount of IL-12. The present invention also relates to a method for prescribing treatment for a respiratory dise... | 10/07/1997 |
| 5674898 | Methods and therapeutic compositions for treating cystic fibrosis Methods and compositions for treating Cystic Fibrosis by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.... | 10/07/1997 |
| 5656256 | Methods of treating lung disease by an aerosol containing benzamil or phenamil Method of hydrating lung mucous secretions in the lungs of a subject are disclosed. The methods involve administering benzamil or phenamil to the lungs of the subject in an amount effective to hydrate lung mucous secretions. The administering step is pref... | 08/12/1997 |
| 5651957 | Method of treating retained pulmonary secretions A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably admini... | 07/29/1997 |
| 5635160 | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is disclosed: ##STR1## wherein: n is from 1 to 6; X is --OH or --SH; A and B are each independently selected from the group consisting of: ##STR2## wherein R is H or Br. T... | 06/03/1997 |
| 5602110 | Method and composition for treating cystic fibrosis A method and composition for treating cystic fibrosis comprising administering to a patient a first component, a second component, and preferably a third component. The first component is an inhibitor which is specific for a cGMP-inhibited type III cAMP p... | 02/11/1997 |
| 5543399 | Cystic fibrosis transmembrane conductance regulator (CFTR) protein A substantially homogeneous protein having cystic fibrosis transmembrane conductance regulator activity is provided. Also provided is a therapeutically effective composition for treating a subject having cystic fibrosis.... | 08/06/1996 |
| 5518729 | Compositions and methods for reparation and prevention of fibrotic lesions In a preferred embodiment, drugs having pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as the active ingredient one or more N-su... | 05/21/1996 |
| 5514665 | Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans Methods for reducing the risk of or preventing infections by bacterial pathogens in vivo. In particular, a method for reducing the risk of P. aeruginosa infection in vivo in compromised hosts such as cystic fibrosis patients. The methods involve the use o... | 05/07/1996 |
| 5512269 | Method of treating retained pulmonary secretions A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably admini... | 04/30/1996 |
| 5502039 | O-derivatized alginic acid antigens O-derivatized alginic acid antigens capable of eliciting opsonizing antibodies in vivo are described. The O-derivatized antigens show enhanced antigenicity and immunogenicity relative to native, non-O-derivatized alginic acid antigens, particularly the ME... | 03/26/1996 |
| 5474760 | Method of inhibiting oxidants using alkylaryl polyether alcohol polymers A method and medicament for the inhibition of oxidants comprising administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. The medicament is preferably administered by aerosolizat... | 12/12/1995 |
| 5464817 | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I The invention is generally directed to methods of promoting normal respiratory tract airflow in subjects with restricted airflow and ciliary clearance caused by the presence of pathological airway contents, and particularly mucoid contents. Actin-binding ... | 11/07/1995 |
| 5441938 | Factors which regulate macrophage antibacterial activity A novel therapy for Pseudomonas aeruginosa infections, in particular in cystic fibrosis patients, is described. Macrophages provide the first line of defence in protecting the lung against bacterial infections. Nonetheless, Pseudomonas aeruginosa infectio... | 08/15/1995 |
| 5384119 | Method of preventing neutrophil mediated connective tissue damage Oligomers of the formula ##STR1## have demonstrated effectiveness in preventing connective tissue damage.... | 01/24/1995 |
| 5310562 | Composition and method for reparation and prevention of fibrotic lesions In a preferred embodiment, drugs having heretofore unknown pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as the active ingredie... | 05/10/1994 |
| 5290815 | Treatment of inflammation and allergy The present invention provides a new medical use for the phenethanolamine compound 4-hydroxy-댑 -[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol and physiologically acceptable salts and solvates thereof in the treatment of ... | 03/01/1994 |
| 5250286 | Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline A method of using an imidazoline compound, which is a vasodilator and an alpha-adrenergic blocking agent, for the treatment of symptoms of chronic obstructive pulmonary diseases (COPD), including cystic fibrosis, chronic bronchitis and emphysema, or COPD ... | 10/05/1993 |
| 5162361 | Method of treating diseases associated with elevated levels of interleukin 1 The present invention relates to a method of treating diseases associated with elevated levels of interleukin 1 (IL-1) including inflammatory diseases such as arthritis, skin hypersensitivity and endotoxemia. More specifically, the invention relates to a ... | 11/10/1992 |
| 5128339 | Proteolytic enzyme inhibition method 4-R4 -R5 -2-Saccharinylmethyl aryl carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R4 -R5 -2-halomethylsaccharin with an arylcarboxylic acid in the presence of an aci... | 07/07/1992 |
| 5104862 | Bethalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone New substituted azetidinones of the general formula (A), which have been found to be potent elastase inhibitors and thereby useful as anti-inflammatory and antidegenerative agents, are described. ##STR1##... | 04/14/1992 |
| 5100647 | Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment Methods for the therapy of cystic fibrosis, Bartter's syndrome, and secretory diarrheas, and for diuretic treatment, by administering to a patient dodecahydro-7,14-methano-2H,6H-di-pyrido[1,2-a:1',2'-e][1,5]diazocine or a pharmaceutically acceptable ... | 03/31/1992 |
| 5100880 | Novel betalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone New substituted azetidinones of the general formula (A), which have been found to be potent elastase inhibitors and thereby useful as anti-inflammatory and antidegenerative agents, are described. ##STR1##... | 03/31/1992 |
| 5096916 | Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline A method of using an imidazoline compound, which is a vasodilator and an alpha-adrenergic blocking agent, for the treatment of symptoms of chronic obstructive pulmonary diseases (COPD), including cystic fibrosis, chronic bronchitis and emphysema, or COPD ... | 03/17/1992 |
| 4866072 | Method of treating cystic fibrosis A method of treatment of cystic fibrosis which comprises administration to a patient suffering from that condition of a therapeutically effective quantity of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rbo xylic acid or ... | 09/12/1989 |
| 4826679 | Composition and methods for alleviating cystic fibrosis The invention relates to an oral composition for alleviating digestive manifestations in patients afflicted with cystic fibrosis, which comprises a therapeutic amount of taurine in association with a pharmaceutically acceptable carrier, and to a method of... | 05/02/1989 |
| 4737519 | Substituted naphthalenes, indoles, benzofurans, and benzothiophenes as lipoxygenase inhibitors The present invention provides certain novel substituted naphthalenes, indoles, benzofurans, and benzothiophenes of Formula I which are useful as inhibitors of leukotriene biosynthesis and as inhibitors of lipoxygenase. They are thus employed wherever it ... | 04/12/1988 |
| 4209443 | Process for separating pharmaceutically active diindole alkaloids A mixture of minor diindole alkaloids from Vinca-containing vinblastine and 4-deacetoxy-vinblastine vines, are separated by subjecting the mixture to a deacetylation to correct the vinblastine to deacetyl-vinblastine prior to chromatographic separation of... | 06/24/1980 |
